Date: 2012-12-16
Type of information: R&D agreement
Compound: small molecule therapeutics developed on the basis of the CavitIIRx platform
Company: Roche (Switzerland) ProMining Therapeutics (Israel)
Therapeutic area: Metabolic diseases
Type agreement:
Action mechanism:
Disease: type 2 diabetes
Details: ProMining Therapeutics has announced a new collaboration with Roche in the field of type 2 diabetes mellitus. Under the terms of the agreement, ProMining Therapeutics will use its CavitIIRx platform to develop small molecule therapeutics for treatment of type 2 diabetes mellitus and will receive research based funding. Further details of the agreement were not disclosed.
Financial terms:
Latest news:
